News & Views | Published:

Class II peptide multimers: promise for type 1A diabetes?

Nature Immunology volume 3, pages 344345 (2002) | Download Citation

Subjects

Lack of proper tools hampers early diagnosis and treatment of antigen-specific autoimmune diseases. A new strategy that makes use of peptide-MHC reagents could control recent-onset diabetes in mice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Nature Immunol., 3, 385–393 (2002).

  2. 2.

    et al. Proc. Natl Acad. Sci. USA 88, 11465–11469 (1991).

  3. 3.

    et al. J. Autoimmun. 8, 787–807 (1995).

  4. 4.

    et al. Nature 406, 739–742 (2000).

  5. 5.

    et al. Proc. Natl Acad. Sci. USA 97, 1701–1706 (2000).

  6. 6.

    et al. Eur. J. Immunol. 25, 1056–1062 (1995).

  7. 7.

    et al. Nature Immunology 2, 501–507 (2001).

  8. 8.

    et al. Diabetes 50, 1274–1281 (2001).

  9. 9.

    et al. J. Clin. Invest. 104, R63–R67 (1999).

  10. 10.

    et al. J. Immunol. 164, 4244–4249 (2000).

  11. 11.

    et al. Proc. Natl Acad. Sci. USA 97, 11433–11438 (2000).

  12. 12.

    et al. 167, 4861–4868 (2001).

Download references

Author information

Affiliations

  1. Barbara Davis Center for Childhood Diabetes, University of Colorado, Denver, Colorado 80262, USA. george.eisenbarth@uchsc.edu

    • George S. Eisenbarth
  2. Benaroya Research Institute, Seattle, Washington 98101, USA. nepom@vmresearch.org

    • Gerald T. Nepom

Authors

  1. Search for George S. Eisenbarth in:

  2. Search for Gerald T. Nepom in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/ni0402-344

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing